BE2017C055I2 - - Google Patents

Info

Publication number: BE2017C055I2
Authority: BE; Belgium

Application number

BE2017C055C

Original Assignee

Wyeth Holdings Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-11

Filing date

2017-11-23

Publication date

2022-02-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C055(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-11-23 Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc

2022-02-01 Publication of BE2017C055I2 publication Critical patent/BE2017C055I2/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
- C12N9/2411—Amylases
- C12N9/2414—Alpha-amylase (3.2.1.1.)
- C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)

BE2017C055C 2001-10-11 2017-11-23 BE2017C055I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US32810101P	2001-10-11	2001-10-11
US40693402P	2002-08-30	2002-08-30
EP02804818.9A EP1442047B1 (fr)	2001-10-11	2002-10-11	Nouvelle compositions immunogenes utilisees pour la prevention et le traitement de la meningococcie

Publications (1)

Publication Number	Publication Date
BE2017C055I2 true BE2017C055I2 (fr)	2022-02-01

Family

ID=27668840

Family Applications (3)

Application Number	Title	Priority Date
BE2017C055C BE2017C055I2 (fr)	2001-10-11	2017-11-23
BE2017C057C BE2017C057I2 (fr)	2001-10-11	2017-11-23
BE2017C056C BE2017C056I2 (fr)	2001-10-11	2017-11-23

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
BE2017C057C BE2017C057I2 (fr)	2001-10-11	2017-11-23
BE2017C056C BE2017C056I2 (fr)	2001-10-11	2017-11-23

Country Status (18)

Country	Link
US (13)	US8101194B2 (fr)
EP (14)	EP2332961B1 (fr)
JP (6)	JP2005515771A (fr)
KR (4)	KR101099916B1 (fr)
CN (4)	CN105617372A (fr)
AU (3)	AU2009213040C1 (fr)
BE (3)	BE2017C055I2 (fr)
BR (1)	BRPI0212999B8 (fr)
CA (5)	CA2918207C (fr)
DK (10)	DK2371838T3 (fr)
ES (14)	ES2562811T3 (fr)
FR (4)	FR15C0056I2 (fr)
IL (5)	IL161052A0 (fr)
LU (4)	LU92786I2 (fr)
MX (3)	MX339524B (fr)
NL (4)	NL300755I2 (fr)
PT (10)	PT2332961T (fr)
WO (1)	WO2003063766A2 (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9910089A (pt)	1998-05-01	2004-06-08	Chiron Corp	Composições e antìgenos de neisseria meningitidis
ES2563650T3 (es)	1999-05-19	2016-03-15	Glaxosmithkline Biologicals Sa	Composiciones de combinaciones de Neisseria
EP2275553B1 (fr)	1999-10-29	2015-05-13	Novartis Vaccines and Diagnostics S.r.l.	Peptides antigéniques de Neisseria
PT1248647E (pt)	2000-01-17	2010-11-18	Novartis Vaccines & Diagnostics Srl	Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
ES2299476T3 (es)	2000-02-28	2008-06-01	Novartis Vaccines And Diagnostics S.R.L.	Expresion hibrida de proteinas de neisseria.
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
MX339524B (es) *	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1549338B1 (fr)	2002-10-11	2010-12-22	Novartis Vaccines and Diagnostics S.r.l.	Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
GB0227346D0 (en) *	2002-11-22	2002-12-31	Chiron Spa	741
ES2383175T3 (es)	2003-01-30	2012-06-18	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
AU2004233012A1 (en) *	2003-04-16	2004-11-04	Wyeth Holdings Corporation	Novel immunogenic compositions for the prevention and treatment of meningococcal disease
PL1670506T3 (pl)	2003-10-02	2013-04-30	Novartis Ag	Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
GB0408977D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) *	2004-09-01	2004-10-06	Chiron Srl	741 chimeric polypeptides
DK1868645T3 (da)	2005-04-08	2012-04-10	Wyeth Llc	Multivalent pneumokok-sakkarid-protein-konjugat-sammensætning
US7709001B2 (en)	2005-04-08	2010-05-04	Wyeth Llc	Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0612655B1 (pt)	2005-06-27	2021-06-15	Pfizer Ireland Pharmaceuticals	Composição imunogênica
AU2013201318B2 (en) *	2005-11-25	2015-11-19	Glaxosmithkline Biologicals Sa	Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
TW200806315A (en) *	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) *	2006-04-26	2016-07-28	Wyeth Llc	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) *	2006-04-26	2017-12-07	Wyeth Llc	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2007277081B2 (en)	2006-07-27	2014-02-06	Wyeth Llc	High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
CA2716212A1 (fr)	2008-02-21	2009-08-27	Novartis Ag	Polypeptides fhbp a meningocoques
WO2010070453A2 (fr)	2008-12-17	2010-06-24	Novartis Ag	Vaccins méningococciques comprenant un récepteur de l'hémoglobine
CN102438649A (zh) *	2009-03-24	2012-05-02	诺华有限公司	脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
NZ595234A (en)	2009-03-24	2013-12-20	Novartis Ag	Adjuvanting meningococcal factor h binding protein
EP2443250B8 (fr)	2009-06-16	2016-09-21	GlaxoSmithKline Biologicals SA	Dosages haut débit de bactéricides opsoniques et dépendant d'anticorps à médiation par le complément
EP2470205A1 (fr)	2009-08-27	2012-07-04	Novartis AG	Adjuvant contenant de l'aluminium, un oligonucléotide et une polycation
EP3017828A1 (fr)	2009-08-27	2016-05-11	GlaxoSmithKline Biologicals SA	Polypeptides hybrides contenant des séquences fhbp à méningocoques
EP2483390A2 (fr)	2009-09-30	2012-08-08	Novartis AG	Expression de polypeptides fhbp méningococciques
CN102917730A (zh)	2009-10-27	2013-02-06	诺华有限公司	修饰的脑膜炎球菌fHBP多肽
EP3327028B1 (fr)	2010-03-30	2022-03-16	Children's Hospital & Research Center at Oakland	Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation
PL3170508T3 (pl)	2010-06-04	2020-04-30	Wyeth Llc	Preparaty szczepionek
CA2803239A1 (fr)	2010-06-25	2011-12-29	Novartis Ag	Associations de proteines de liaison du facteur h meningococcique
ES2994878T3 (en) *	2010-08-23	2025-02-03	Wyeth Llc	Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko)	2010-09-10	2016-01-22	와이어쓰 엘엘씨	네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
AU2011300418B2 (en)	2010-09-10	2016-05-12	Glaxosmithkline Biologicals Sa	Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201015132D0 (en) *	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
CA2828844C (fr)	2011-03-02	2020-07-14	Novartis Ag	Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
WO2012153302A1 (fr)	2011-05-12	2012-11-15	Novartis Ag	Antipyrétiques pour améliorer la tolérabilité de vaccins à base de vésicules
JP2015505309A (ja)	2011-12-29	2015-02-19	ノバルティスアーゲー	髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
ES2654613T3 (es)	2012-02-02	2018-02-14	Glaxosmithkline Biologicals Sa	Promotores para una expresión aumentada de proteínas en meningococos
JP2015517089A (ja)	2012-03-08	2015-06-18	ノバルティスアーゲー	タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
EP2822584A1 (fr)	2012-03-08	2015-01-14	Novartis AG	Vaccins combinés comprenant des agonistes du tlr4
BR122016004924A2 (pt) *	2012-03-09	2019-07-30	Pfizer Inc.	Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ630133A (en) *	2012-06-14	2016-10-28	Novartis Ag	Vaccines for serogroup x meningococcus
CN104736563A (zh)	2012-07-27	2015-06-24	国家健康与医学研究院	Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
CA2882619A1 (fr)	2012-09-06	2014-03-13	Novartis Ag	Vaccins combinatoires avec meningococcus de serogroupe b et d/t/p
EP2964665B1 (fr)	2013-03-08	2018-08-01	Pfizer Inc	Polypeptides immunogènes de fusion
US9914756B2 (en)	2013-08-02	2018-03-13	Children's Hospital & Research Center At Oakland	Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
CA2923129C (fr) *	2013-09-08	2020-06-09	Pfizer Inc.	Compositions utilisables contre neisseria meningitidis et procedes associes
RS61246B1 (sr)	2014-02-28	2021-01-29	Glaxosmithkline Biologicals Sa	Modifikovani meningokokni fhbp polipeptidi
CN106715464B (zh)	2014-07-23	2021-03-16	奥克兰儿童医院及研究中心	因子h结合蛋白变体及其使用方法
US11031102B2 (en)	2014-11-17	2021-06-08	Alexion Pharmaceuticals, Inc.	Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
WO2016132294A1 (fr)	2015-02-19	2016-08-25	Pfizer Inc.	Compositions de neisseria meningitidis et méthodes associées
EP3263695A1 (fr)	2016-06-29	2018-01-03	GlaxoSmithKline Biologicals SA	Compositions immunogènes
CN106434720A (zh) *	2016-08-03	2017-02-22	中国医学科学院医学生物学研究所	提高脑膜炎奈瑟菌fHBP蛋白表达的方法
GB201614687D0 (en) *	2016-08-31	2016-10-12	Univ Oxford Innovation Ltd	fHbp scaffold
US12161707B2 (en)	2016-09-02	2024-12-10	Glaxosmithkline Biologicals Sa	Vaccines for Neisseria gonorrhoeae
EP4309670A3 (fr)	2016-09-02	2024-07-17	Sanofi Pasteur, Inc.	Vaccin contre neisseria meningitidis
US10738338B2 (en)	2016-10-18	2020-08-11	The Research Foundation for the State University	Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US10183070B2 (en)	2017-01-31	2019-01-22	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
JP6856762B2 (ja) *	2017-09-28	2021-04-14	富士フイルム株式会社	撮像装置、情報取得方法及び情報取得プログラム
WO2019065555A1 (fr)	2017-09-28	2019-04-04	富士フイルム株式会社	Dispositif de capture d'images, procédé d'acquisition d'informations et programme d'acquisition d'informations
TWI687696B (zh) *	2019-06-26	2020-03-11	國立中興大學	回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
WO2021059181A1 (fr)	2019-09-27	2021-04-01	Pfizer Inc.	Compositions de neisseria meningitidis et méthodes associées
CN114681601B (zh) *	2020-12-31	2025-08-19	基础治疗有限公司	脑膜炎奈瑟氏球菌疫苗及其应用
TW202245836A (zh) *	2021-02-19	2022-12-01	美商賽諾菲巴斯德公司	重組ｂ型腦膜炎球菌疫苗
GB202115077D0 (en)	2021-10-21	2021-12-08	Glaxosmithkline Biologicals Sa	Assay
CN118613207A (zh)	2022-01-24	2024-09-06	皇家飞利浦有限公司	使用血管内数据与管腔外图像之间的共配准的脉搏波速度确定以及相关联的系统、设备和方法
GB202208089D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition
GB202208093D0 (en)	2022-06-01	2022-07-13	Glaxosmithkline Biologicals Sa	Immunogenic composition
TW202423477A (zh)	2022-08-03	2024-06-16	美商賽諾菲巴斯德公司	針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025199107A1 (fr)	2024-03-19	2025-09-25	Alexion Pharmaceuticals, Inc.	Stratégie d'évaluation et de gestion des risques impliquant un suivi des patients dans le cadre de l'utilisation ou de l'interruption d'un inhibiteur du complément
CN120227449A (zh) *	2025-05-21	2025-07-01	苏州聚微生物科技有限公司	B群脑膜炎球菌疫苗组合物及其制备方法与应用
CN120241991B (zh) *	2025-06-05	2025-12-23	北京绿竹生物技术股份有限公司	一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT280356B (de)	1968-03-06	1970-04-10	Telefonbau & Normalzeit Gmbh	Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4554101A (en)	1981-01-09	1985-11-19	New York Blood Center, Inc.	Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it)	1983-02-08	1987-04-15	Sclavo Spa	Procedimento per la produzione di proteine correlate alla tossina difterica.
CA1247080A (fr)	1983-03-08	1988-12-20	Commonwealth Serum Laboratories Commission	Sequences d'acides amines ayant une activite antigenique
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4650764A (en)	1983-04-12	1987-03-17	Wisconsin Alumni Research Foundation	Helper cell
US4668829A (en) *	1984-07-18	1987-05-26	University Patents, Inc.	Ferroelectric smectic liquid crystals
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8424757D0 (en)	1984-10-01	1984-11-07	Pasteur Institut	Retroviral vector
SE8405493D0 (sv)	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr)	1984-11-20	1989-02-17	Pasteur Institut	Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (fr)	1985-08-15	1987-02-26	Stauffer Chemical Company	Microorganisme producteur de tryptophane
US5078996A (en)	1985-08-16	1992-01-07	Immunex Corporation	Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
EP0247091B1 (fr)	1985-11-01	1993-09-29	Xoma Corporation	Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
US4861719A (en)	1986-04-25	1989-08-29	Fred Hutchinson Cancer Research Center	DNA constructs for retrovirus packaging cell lines
US5514581A (en) *	1986-11-04	1996-05-07	Protein Polymer Technologies, Inc.	Functional recombinantly prepared synthetic protein polymer
US4980289A (en)	1987-04-27	1990-12-25	Wisconsin Alumni Research Foundation	Promoter deficient retroviral vector
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
RU2023448C1 (ru)	1987-07-30	1994-11-30	Сентро Насьональ Де Биопрепарадос	Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
JPH01144977A (ja)	1987-11-30	1989-06-07	Agency Of Ind Science & Technol	新規組換えプラスミドｐＴＰＧＩＦ２
CA1315719C (fr)	1988-02-05	1993-04-06	Arthur Bank	Lignees cellulaires utilisees pour l'encapsidation de retrovirus et modes d'utilisation
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
CA1339354C (fr)	1988-09-01	1997-08-26	The Whitehead Institute For Biomedical Research	Retrovirus recombinants avec spectres d'activite amphotropes et ecotropes
US7118757B1 (en) *	1988-12-19	2006-10-10	Wyeth Holdings Corporation	Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en)	1989-01-12	1992-06-23	Wisconsin Alumni Research Foundation	Recombination resistant retroviral helper cell and products produced thereby
DE69033600T2 (de)	1989-03-09	2001-04-05	American Cyanamid Co., Madison	Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
US5354844A (en)	1989-03-16	1994-10-11	Boehringer Ingelheim International Gmbh	Protein-polycation conjugates
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
WO1990014837A1 (fr)	1989-05-25	1990-12-13	Chiron Corporation	Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
CA2039921A1 (fr)	1990-04-16	1991-10-17	Xandra O. Breakefield	Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (fr)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Vecteurs eucaryotiques a base de virus adeno-associes (aav)
EP0467714A1 (fr)	1990-07-19	1992-01-22	Merck & Co. Inc.	Classe II de la membrane extérieure de Neisseria meningitidis et raccins la contenant
JPH0453645U (fr) *	1990-09-12	1992-05-07
WO1992005263A1 (fr)	1990-09-25	1992-04-02	Cantab Pharmaceuticals Research Limited	Vaccin viral mutant a genome deficient et produit en transcomplementant la lignee cellulaire
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
IL101715A (en)	1991-05-02	2005-06-19	Amgen Inc	Recombinant dna-derived cholera toxin subunit analogs
WO1993007897A1 (fr)	1991-10-21	1993-04-29	Medimmune, Inc.	Vecteurs d'expression bacteriens contenant de l'adn codant des signaux de secretion de lipoproteines
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
IT1253009B (it)	1991-12-31	1995-07-10	Sclavo Ricerca S R L	Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (fr) *	1992-01-24	1993-08-05	Cornell Research Foundation, Inc.	HOLOENZYME ADN POLYMERASE III et E. COLI ET SOUS-UNITES
WO1994012649A2 (fr)	1992-12-03	1994-06-09	Genzyme Corporation	Therapie genique de la fibrose kystique
ES2231770T3 (es)	1993-03-05	2005-05-16	Wyeth Holdings Corporation	Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
CA2158148A1 (fr)	1993-03-19	1994-09-29	Stephen Charles Inglis	Virus defectif mutant non retroviral (par ex. hsv), utilise comme vaccin
EP0624376B1 (fr)	1993-05-13	2000-03-15	American Cyanamid Company	Préparation et utilisations de protéines de membranes externes dépouvues de LOS à partir de coques gram-négatifs
FR2705361B1 (fr)	1993-05-18	1995-08-04	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr)	1993-05-28	1995-08-18	Transgene Sa	Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
AU7264694A (en)	1993-07-13	1995-02-13	Rhone-Poulenc Rorer S.A.	Defective adenovirus vectors and use thereof in gene therapy
US5439808A (en) *	1993-07-23	1995-08-08	North American Vaccine, Inc.	Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
WO1995007358A1 (fr)	1993-07-30	1995-03-16	University Of Medicine & Dentistry Of New Jersey	Transfert efficace de genes dans des lymphocytes primaires
FR2708622B1 (fr)	1993-08-02	1997-04-18	Raymond Hamers	Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) *	1993-12-27	1996-08-27	Rutgers, The State University Of New Jersey	Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr)	1994-01-10	1996-03-22	Rhone Poulenc Rorer Sa	Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr)	1994-02-08	1996-04-12	Rhone Poulenc Rorer Sa	Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi)	1994-02-21	1997-04-10	Arto Remes	Laite inkontinenssihoitoa varten
FR2716459B1 (fr)	1994-02-22	1996-05-10	Univ Paris Curie	Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (fr)	1994-03-25	1995-10-05	The Uab Research Foundation	Composition et methodes d'obtention de cellules productrices de virus de recombinaison isogeniques
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
WO1995028494A1 (fr)	1994-04-15	1995-10-26	Targeted Genetics Corporation	Proteine de fusion d'apport de gene
US5571515A (en)	1994-04-18	1996-11-05	The Wistar Institute Of Anatomy & Biology	Compositions and methods for use of IL-12 as an adjuvant
EP0710118B1 (fr) *	1994-04-20	1998-11-25	U.S. Department Of The Army	Vaccin contre les infections par des bacteries gram-negatives
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5565204A (en)	1994-08-24	1996-10-15	American Cyanamid Company	Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en)	1994-09-28	1998-11-17	American Home Products Corporation	Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en)	1994-11-02	1994-12-21	Biocine Spa	Combined meningitis vaccine
FR2727679B1 (fr)	1994-12-05	1997-01-03	Rhone Poulenc Rorer Sa	Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr)	1994-12-27	1996-10-01	Solvay	Adjuvants pour vaccins.
IL116816A (en)	1995-01-20	2003-05-29	Rhone Poulenc Rorer Sa	Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr)	1995-02-17	1997-03-28	Rhone Poulenc Rorer Sa	Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en)	1995-03-17	2008-03-20	Bernard Brodeur	MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
WO1996039036A1 (fr)	1995-06-05	1996-12-12	The University Of Alabama At Birmingham Research Foundation	Procedes et composition de creation de cellules syngeniques productrices de virus recombines
FI974422L (fi) *	1995-06-07	1998-02-04	Connaught Lab	Lipoproteiinien ilmentäminen
FR2741358B1 (fr)	1995-11-17	1998-01-02	Centre Nat Rech Scient	Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) *	1996-01-17	1999-05-03	Ct Ingenieria Genetica Biotech	Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5846547A (en)	1996-01-22	1998-12-08	Regents Of The University Of Minnesota	Streptococcal C5a peptidase vaccine
US6355255B1 (en)	1998-12-07	2002-03-12	Regents Of The University Of Minnesota	Streptococcal C5a peptidase vaccine
CA2264585C (fr)	1996-08-27	2005-06-14	Chiron Corporation	Anticorps monoclonaux definissant des epitopes meningococciques b et leurs utilisations dans la preparation de compositions vaccinales
ATE208629T1 (de)	1996-08-27	2001-11-15	Chiron Corp	Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
GB9622159D0 (en)	1996-10-24	1996-12-18	Solvay Sociutu Anonyme	Polyanionic polymers as adjuvants for mucosal immunization
AU5426098A (en)	1996-10-24	1998-05-15	Emory University	Invasion associated genes from (neisseria meningitidis) serogroup
GB9622660D0 (en)	1996-10-31	1997-01-08	Biocine Spa	Immunogenic detoxified mutant toxin
US6113918A (en)	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de)	1997-06-02	2001-08-23	Siemens Ag	Bildrekonstruktionsverfahren für einen Computertomographen
ATE290403T1 (de)	1997-06-30	2005-03-15	Roussy Inst Gustave	Verbesserung der verabreichung der nukleinsäure in zellen der plurizellulären eukaryotischen organismen und kombination zur durchführung des verfahrens
JP2002507985A (ja)	1997-06-30	2002-03-12	ローヌ−プーラン・ロレ・エス・アー	横紋筋に核酸を導入する改良法およびその組合せ
JP2002515816A (ja)	1997-06-30	2002-05-28	アバンテイス・フアルマ・エス・アー	ｉｎｖｉｖｏ組織に核酸ベクターを最適に電気導入する装置
WO1999003501A1 (fr) *	1997-07-17	1999-01-28	North American Vaccine, Inc.	CONJUGUES IMMUNOGENES RENFERMANT UNE PORINE MENINGOCOCCIQUE DU GROUPE B ET UN POLYSACCHARIDE $i(H. INFLUENZAE)
JPH1144977A (ja)	1997-07-25	1999-02-16	Copyer Co Ltd	画像形成装置
AU9120898A (en)	1997-08-27	1999-03-16	Chiron Corporation	Molecular mimetics of meningococcal b epitopes
CN1271366A (zh) *	1997-08-29	2000-10-25	陶氏化学公司	均质填充聚合物复合材料
ATE476508T1 (de)	1997-11-06	2010-08-15	Novartis Vaccines & Diagnostic	Neisseriale antigene
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ES2333071T5 (es)	1998-01-14	2015-08-17	Novartis Vaccines And Diagnostics S.R.L.	Antígenos de Neisseria meningitidis
BR9909097A (pt) *	1998-02-03	2000-12-05	Ct Disease Contr & Prevention	Molécula hìbrida de ácido nucleico, vetor de expressão, processos para preparação e para a produção de proteìna psaa lipidada recombinante, proteìna psaa lipidada isolada e purificada produzida recombinantemente, composição imunológica, processos para induzir uma resposta imunológica em um animal e para imunizar um hospedeiro contra infecção pneumocócica, e, composição imunogênica para administração intranasal a um hospedeiro
GB9806456D0 (en)	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
GB9808734D0 (en)	1998-04-23	1998-06-24	Smithkline Beecham Biolog	Novel compounds
GB9808932D0 (en)	1998-04-27	1998-06-24	Chiron Spa	Polyepitope carrier protein
BR9910089A (pt)	1998-05-01	2004-06-08	Chiron Corp	Composições e antìgenos de neisseria meningitidis
DE69934225T2 (de)	1998-05-29	2007-09-27	Novartis Vaccines and Diagnostics, Inc., Emeryville	Kombinierte meningitis b/c impfstoffe
AU1199900A (en) *	1998-09-30	2000-04-17	Walter Reed Army Institute Of Research	Use of purified invaplex from gram negative bacteria as a vaccine
ATE378066T1 (de)	1998-09-30	2007-11-15	Wyeth Corp	Mutiertes cholera holotoxin als hilfsmittel
JP2004511201A (ja)	1998-10-09	2004-04-15	カイロン　コーポレイション	ナイセリアゲノム配列およびそれらの使用方法
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US6281337B1 (en)	1998-11-12	2001-08-28	Schering Corporation	Methods for conversion of protein isoforms
CA2359486A1 (fr)	1999-01-15	2000-07-20	Smithkline Beecham Biologicals S.A.	Polypeptides basb052 de neisseria meningitidis
AU2292800A (en)	1999-01-22	2000-08-07	Smithkline Beecham Biologicals (Sa)	Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides andprotective antibodies
GB9902084D0 (en)	1999-01-29	1999-03-24	Smithkline Beecham Biolog	Novel compounds
ES2313881T3 (es)	1999-02-05	2009-03-16	MERCK & CO., INC.	Formulaciones de vacunas frente al papilomavirus humano.
WO2000050075A2 (fr)	1999-02-26	2000-08-31	Chiron S.P.A.	Developpement de l'activite bactericide des antigenes de neisseria a l'aide d'oligonucleotides a motifs cg
US6245568B1 (en)	1999-03-26	2001-06-12	Merck & Co., Inc.	Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en)	1999-04-27	2006-10-03	Chiron Srl	Immunogenic detoxified mutant E. coli LT-A-toxin
WO2000066741A2 (fr)	1999-04-30	2000-11-09	Chiron S.P.A.	Antigenes de neisseria conserves
CN1359426A (zh)	1999-04-30	2002-07-17	希龙公司	奈瑟球菌基因组序列及其用法
ES2563650T3 (es) *	1999-05-19	2016-03-15	Glaxosmithkline Biologicals Sa	Composiciones de combinaciones de Neisseria
GB9911683D0 (en)	1999-05-19	1999-07-21	Chiron Spa	Antigenic peptides
GB9916529D0 (en)	1999-07-14	1999-09-15	Chiron Spa	Antigenic peptides
GB9918319D0 (en) *	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US7384640B1 (en)	1999-09-30	2008-06-10	Wyeth Holdings Corporation	Mutant cholera holotoxin as an adjuvant
EP2275553B1 (fr)	1999-10-29	2015-05-13	Novartis Vaccines and Diagnostics S.r.l.	Peptides antigéniques de Neisseria
BR0015961A (pt)	1999-11-29	2003-06-10	Chiron Spa	Antìgeno de neisseria de 85kda
GB9928196D0 (en) *	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
JP4948731B2 (ja)	1999-12-02	2012-06-06	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	凍結乾燥の際に生物学的分子を安定化するための組成物および方法
PT1248647E (pt) *	2000-01-17	2010-11-18	Novartis Vaccines & Diagnostics Srl	Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
ES2299476T3 (es)	2000-02-28	2008-06-01	Novartis Vaccines And Diagnostics S.R.L.	Expresion hibrida de proteinas de neisseria.
RU2293573C2 (ru)	2000-06-08	2007-02-20	Интерселл Аг	Иммуностимулирующие олигодезоксинуклеотиды
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
KR100947757B1 (ko)	2001-01-23	2010-03-18	아벤티스 파스퇴르	다가 수막구균 폴리사카라이드―단백질 접합체 백신
GB0103424D0 (en) *	2001-02-12	2001-03-28	Chiron Spa	Gonococcus proteins
WO2002079246A2 (fr)	2001-03-30	2002-10-10	Geneprot, Inc.	Compositions proteiques humaines riches en arginine-
AU2002258734A1 (en)	2001-04-13	2002-10-28	Wyeth Holdings Corporation	Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
US7534444B2 (en)	2001-04-17	2009-05-19	Novattis Vaccines And Diagnostics, Inc.	Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
ATE451386T1 (de)	2001-06-07	2009-12-15	Wyeth Corp	Mutantenformen von cholera holotoxin als adjuvans
JP2005508143A (ja)	2001-06-07	2005-03-31	ワイス・ホールデイングス・コーポレーシヨン	アジュバントとしてのコレラホロトキシンの突然変異形
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
CA2452720C (fr)	2001-07-26	2012-04-17	Chiron S.R.L.	Vaccins comprenant des adjuvants aluminium et histidine
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
CA2460546A1 (fr)	2001-09-14	2003-03-27	Invitrogen Corporation	Adn polymerases et mutants correspondants
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en)	2001-12-04	2002-01-23	Chiron Spa	Adjuvanted antigenic meningococcal compositions
EP1490409B1 (fr)	2002-03-26	2008-12-31	Novartis Vaccines and Diagnostics S.r.l.	Saccharides modifies presentant une stabilite amelioree dans l'eau
GB0302218D0 (en)	2003-01-30	2003-03-05	Chiron Sri	Vaccine formulation & Mucosal delivery
WO2003094960A2 (fr)	2002-05-14	2003-11-20	Chiron Srl	Vaccins combines destines a etre administres aux muqueuses pour l'immunisation contre la meningite bacterienne
DE60328481D1 (de)	2002-05-14	2009-09-03	Novartis Vaccines & Diagnostic	Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
US7785608B2 (en) *	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220198D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Modified saccharides,conjugates thereof and their manufacture
EP1549338B1 (fr)	2002-10-11	2010-12-22	Novartis Vaccines and Diagnostics S.r.l.	Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
DK2279746T3 (da)	2002-11-15	2013-11-25	Novartis Vaccines & Diagnostic	Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
EP1590459A2 (fr) *	2003-01-15	2005-11-02	Wyeth Holdings Corporation	Methodes d augmentation de l expression de la proteine neisseria et compositions associees
ES2383175T3 (es)	2003-01-30	2012-06-18	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
WO2004083251A2 (fr)	2003-03-17	2004-09-30	Wyeth Holdings Corporation	Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
AU2004233012A1 (en)	2003-04-16	2004-11-04	Wyeth Holdings Corporation	Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US9107831B2 (en)	2003-06-02	2015-08-18	Novartis Vaccines And Diagonstics, Inc.	Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
US20050019337A1 (en)	2003-06-23	2005-01-27	Ryall Robert P.	Immunization method against Neisseria meningitidis serogroups A and C
GB0316560D0 (en)	2003-07-15	2003-08-20	Chiron Srl	Vesicle filtration
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
PL1670506T3 (pl)	2003-10-02	2013-04-30	Novartis Ag	Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
WO2005065708A2 (fr)	2003-12-30	2005-07-21	Wyeth	Formulations de proteines hydrophobes dans une composition immunogenique a tolerabilite amelioree
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
GB0408977D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en)	2004-04-22	2004-05-26	Chiron Srl	Meningococcal fermentation for preparing conjugate vaccines
WO2005105140A2 (fr)	2004-04-30	2005-11-10	Chiron Srl	Integration d'une vaccination conjuguee antimeningococcique
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0410220D0 (en)	2004-05-07	2004-06-09	Kirkham Lea Ann	Mutant pneumolysin proteins
GB0411387D0 (en)	2004-05-21	2004-06-23	Chiron Srl	Analysis of saccharide length
GB0413868D0 (en)	2004-06-21	2004-07-21	Chiron Srl	Dimensional anlaysis of saccharide conjugates
WO2006011060A2 (fr)	2004-07-23	2006-02-02	Chiron Srl	Polypeptides pour assemblage oligomere d'antigenes
GB0419408D0 (en)	2004-09-01	2004-10-06	Chiron Srl	741 chimeric polypeptides
GB0419846D0 (en)	2004-09-07	2004-10-13	Chiron Srl	Vaccine adjuvants for saccharides
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en)	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
CN101107007B (zh)	2005-01-27	2011-08-17	奥克兰儿童医院及研究中心	对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
EP1855595A2 (fr)	2005-03-07	2007-11-21	ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America	Compositions pharmaceutiques liposomales
NZ563940A (en)	2005-05-06	2010-11-26	Novartis Vaccines & Diagnostic	Immunogens for meningitidis-A vaccines comprising oligosaccharides linked by a phosphonate
BRPI0612655B1 (pt)	2005-06-27	2021-06-15	Pfizer Ireland Pharmaceuticals	Composição imunogênica
AU2006286228A1 (en)	2005-09-01	2007-03-08	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Multiple vaccination including serogroup C meningococcus
ES2522521T3 (es)	2005-09-05	2014-11-14	Glaxosmithkline Biologicals Sa	Ensayo bactericida del suero para antisueros específicos de N. meningitidis
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
EA200801368A1 (ru)	2005-12-23	2008-12-30	Глаксосмитклайн Байолоджикалс С.А.	Конъюгатные вакцины
PL2004225T3 (pl)	2006-03-22	2012-09-28	Novartis Ag	Schematy immunizacji koniugatami meningokokowymi
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007127668A2 (fr)	2006-04-26	2007-11-08	Wyeth	Nouveaux procedes de revetement d'un contenant empechant la precipitation de formulations de conjugues de polysaccharide-proteine
US20090123499A1 (en)	2006-06-12	2009-05-14	Nathalie Devos	Vaccine
GB0612854D0 (en)	2006-06-28	2006-08-09	Novartis Ag	Saccharide analysis
MX2008016280A (es)	2006-06-29	2009-03-26	Novartis Ag	Polipeptidos a partir de neisseria meningitidis.
AU2007277081B2 (en)	2006-07-27	2014-02-06	Wyeth Llc	High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) *	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
AU2008259423A1 (en)	2007-06-04	2008-12-11	Novartis Ag	Formulation of meningitis vaccines
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
EP2185576A4 (fr) *	2007-08-02	2011-01-12	Childrens Hosp & Res Ct Oak	Vaccins vésiculaires à base de fhbp et de lpxl1 pour une protection à large spectre contre les maladies à neisseria meningitidis
BR122016015627A2 (pt)	2007-10-19	2018-10-30	Novartis Ag	kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
CA2716212A1 (fr)	2008-02-21	2009-08-27	Novartis Ag	Polypeptides fhbp a meningocoques
JP5689687B2 (ja)	2008-03-05	2015-03-25	サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ	アジュバント含有ワクチン組成物の安定化方法
EP2631245A1 (fr)	2008-03-10	2013-08-28	Children's Hospital & Research Center at Oakland	Protéines chimères de liaison du facteur H contenant un domaine B hétérologue, et procédés d utilisation associés
WO2009143168A2 (fr)	2008-05-19	2009-11-26	Novartis Ag	Essais de vaccin
AU2009262893B2 (en)	2008-05-30	2015-05-21	The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research	Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
EP2326726A4 (fr)	2008-08-27	2011-09-28	Childrens Hosp & Res Ct Oak	Dosages fondés sur le facteur h du complément pour déterminer une activité sérique bactéricide contre neisseria meningitidis
US8470340B2 (en)	2008-09-03	2013-06-25	Children's Hospital & Research Center Oakland	Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it)	2008-09-12	2012-06-06	Novartis Vaccines & Diagnostic	Immunogeni di proteine che legano il fattore h.
AR073997A1 (es)	2008-10-29	2010-12-15	Wyeth Corp	Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
JP5410084B2 (ja) *	2008-12-15	2014-02-05	川上産業株式会社	梱包箱及び箱状芯材
WO2010070453A2 (fr)	2008-12-17	2010-06-24	Novartis Ag	Vaccins méningococciques comprenant un récepteur de l'hémoglobine
NZ595234A (en)	2009-03-24	2013-12-20	Novartis Ag	Adjuvanting meningococcal factor h binding protein
CN102438649A (zh)	2009-03-24	2012-05-02	诺华有限公司	脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
MX2011011512A (es)	2009-04-30	2012-02-13	Novartis Vaccines & Diagnostic	Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
US9365885B2 (en)	2009-06-16	2016-06-14	Puiying Annie Mak	High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
EP3017828A1 (fr)	2009-08-27	2016-05-11	GlaxoSmithKline Biologicals SA	Polypeptides hybrides contenant des séquences fhbp à méningocoques
IT1395574B1 (it)	2009-09-14	2012-10-16	Guala Dispensing Spa	Dispositivo di erogazione
EP2483390A2 (fr)	2009-09-30	2012-08-08	Novartis AG	Expression de polypeptides fhbp méningococciques
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
JP3158225U (ja) *	2009-10-22	2010-03-25	王　文燦	折畳める物置袋
CN102917730A (zh)	2009-10-27	2013-02-06	诺华有限公司	修饰的脑膜炎球菌fHBP多肽
JP5781542B2 (ja)	2009-12-30	2015-09-24	ノバルティスアーゲー	Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Conjugation process
US20130004530A1 (en)	2010-03-10	2013-01-03	Jan Poolman	Vaccine composition
WO2012020326A1 (fr)	2010-03-18	2012-02-16	Novartis Ag	Vaccins adjuvantés contre le méningocoque de sérogroupe b
EP3327028B1 (fr)	2010-03-30	2022-03-16	Children's Hospital & Research Center at Oakland	Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation
CA2803239A1 (fr)	2010-06-25	2011-12-29	Novartis Ag	Associations de proteines de liaison du facteur h meningococcique
ES2994878T3 (en)	2010-08-23	2025-02-03	Wyeth Llc	Stable formulations of neisseria meningitidis rlp2086 antigens
ES2744471T3 (es)	2010-09-04	2020-02-25	Glaxosmithkline Biologicals Sa	Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
KR101584871B1 (ko)	2010-09-10	2016-01-22	와이어쓰 엘엘씨	네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
AU2011300418B2 (en)	2010-09-10	2016-05-12	Glaxosmithkline Biologicals Sa	Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
US20120070457A1 (en)	2010-09-10	2012-03-22	J. Craig Venter Institute, Inc.	Polypeptides from neisseria meningitidis
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
CA2828844C (fr)	2011-03-02	2020-07-14	Novartis Ag	Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
WO2012134975A1 (fr)	2011-03-28	2012-10-04	St. Jude Children's Research Hospital	Méthodes et compositions utilisant des protéines de fusion immunogènes
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt)	2012-03-09	2019-07-30	Pfizer Inc.	Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
EP2964665B1 (fr)	2013-03-08	2018-08-01	Pfizer Inc	Polypeptides immunogènes de fusion
US9965924B2 (en)	2013-07-15	2018-05-08	Ahmnon D. Moskowitz	Methods, systems, and apparatus for playing multi-zone 21
CA2923129C (fr)	2013-09-08	2020-06-09	Pfizer Inc.	Compositions utilisables contre neisseria meningitidis et procedes associes
WO2016132294A1 (fr)	2015-02-19	2016-08-25	Pfizer Inc.	Compositions de neisseria meningitidis et méthodes associées
US10183070B2 (en)	2017-01-31	2019-01-22	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof

2001
- 2001-10-11 MX MX2012002655A patent/MX339524B/es unknown
2002
- 2002-10-11 ES ES10182611.3T patent/ES2562811T3/es not_active Expired - Lifetime
- 2002-10-11 EP EP10182298.9A patent/EP2332961B1/fr not_active Expired - Lifetime
- 2002-10-11 EP EP10182544.6A patent/EP2371837B1/fr not_active Expired - Lifetime
- 2002-10-11 CA CA2918207A patent/CA2918207C/fr not_active Expired - Lifetime
- 2002-10-11 PT PT101822989T patent/PT2332961T/pt unknown
- 2002-10-11 DK DK10182611.3T patent/DK2371838T3/en active
- 2002-10-11 PT PT101824373T patent/PT2348035E/pt unknown
- 2002-10-11 EP EP20100183020 patent/EP2343308B1/fr not_active Expired - Lifetime
- 2002-10-11 DK DK10183020.6T patent/DK2343308T3/en active
- 2002-10-11 US US10/492,427 patent/US8101194B2/en active Active
- 2002-10-11 ES ES10183020.6T patent/ES2532640T3/es not_active Expired - Lifetime
- 2002-10-11 PT PT101830206T patent/PT2343308E/pt unknown
- 2002-10-11 MX MXPA04003356A patent/MXPA04003356A/es active IP Right Grant
- 2002-10-11 JP JP2003563462A patent/JP2005515771A/ja active Pending
- 2002-10-11 DK DK10182298.9T patent/DK2332961T3/en active
- 2002-10-11 DK DK17156888.4T patent/DK3199539T3/da active
- 2002-10-11 CA CA2894296A patent/CA2894296C/fr not_active Expired - Lifetime
- 2002-10-11 ES ES10182590.9T patent/ES2561430T3/es not_active Expired - Lifetime
- 2002-10-11 ES ES10182324.3T patent/ES2549764T3/es not_active Expired - Lifetime
- 2002-10-11 DK DK10182345.8T patent/DK2341063T3/en active
- 2002-10-11 DK DK10182590.9T patent/DK2348036T3/en active
- 2002-10-11 EP EP10182487.8A patent/EP2371836B1/fr not_active Expired - Lifetime
- 2002-10-11 IL IL16105202A patent/IL161052A0/xx active IP Right Grant
- 2002-10-11 CA CA2939781A patent/CA2939781C/fr not_active Expired - Lifetime
- 2002-10-11 EP EP17156888.4A patent/EP3199539B1/fr not_active Expired - Lifetime
- 2002-10-11 DK DK10182324.3T patent/DK2351767T3/en active
- 2002-10-11 ES ES10182437.3T patent/ES2532639T3/es not_active Expired - Lifetime
- 2002-10-11 ES ES02804818.9T patent/ES2568895T3/es not_active Expired - Lifetime
- 2002-10-11 EP EP02804818.9A patent/EP1442047B1/fr not_active Expired - Lifetime
- 2002-10-11 EP EP10182345.8A patent/EP2341063B1/fr not_active Expired - Lifetime
- 2002-10-11 ES ES10182364.9T patent/ES2609039T3/es not_active Expired - Lifetime
- 2002-10-11 CA CA2463476A patent/CA2463476C/fr not_active Expired - Lifetime
- 2002-10-11 CA CA2849427A patent/CA2849427C/fr not_active Expired - Lifetime
- 2002-10-11 DK DK10182469.6T patent/DK2341062T3/en active
- 2002-10-11 KR KR1020107002131A patent/KR101099916B1/ko not_active Expired - Lifetime
- 2002-10-11 KR KR1020107022714A patent/KR20100121699A/ko not_active Withdrawn
- 2002-10-11 ES ES10182345.8T patent/ES2549765T3/es not_active Expired - Lifetime
- 2002-10-11 PT PT101825909T patent/PT2348036E/pt unknown
- 2002-10-11 PT PT101824878T patent/PT2371836T/pt unknown
- 2002-10-11 WO PCT/US2002/032369 patent/WO2003063766A2/fr not_active Ceased
- 2002-10-11 CN CN201511028093.XA patent/CN105617372A/zh active Pending
- 2002-10-11 PT PT101823458T patent/PT2341063E/pt unknown
- 2002-10-11 ES ES10182487.8T patent/ES2615206T3/es not_active Expired - Lifetime
- 2002-10-11 DK DK10182487.8T patent/DK2371836T3/en active
- 2002-10-11 CN CN201210209882.3A patent/CN102836426B/zh not_active Expired - Lifetime
- 2002-10-11 PT PT101824696T patent/PT2341062T/pt unknown
- 2002-10-11 KR KR1020117022199A patent/KR101215664B1/ko not_active Expired - Lifetime
- 2002-10-11 EP EP10182611.3A patent/EP2371838B1/fr not_active Expired - Lifetime
- 2002-10-11 BR BRPI0212999A patent/BRPI0212999B8/pt not_active IP Right Cessation
- 2002-10-11 EP EP10182324.3A patent/EP2351767B1/fr not_active Expired - Lifetime
- 2002-10-11 CN CN028233301A patent/CN1578785B/zh not_active Expired - Lifetime
- 2002-10-11 PT PT171568884T patent/PT3199539T/pt unknown
- 2002-10-11 DK DK10182437.3T patent/DK2348035T3/en active
- 2002-10-11 EP EP10182399.5A patent/EP2366707B1/fr not_active Expired - Lifetime
- 2002-10-11 EP EP20100182437 patent/EP2348035B1/fr not_active Expired - Lifetime
- 2002-10-11 CN CN201210211368.3A patent/CN102755631B/zh not_active Expired - Lifetime
- 2002-10-11 PT PT101826113T patent/PT2371838E/pt unknown
- 2002-10-11 ES ES17156888T patent/ES2781213T3/es not_active Expired - Lifetime
- 2002-10-11 ES ES10182544.6T patent/ES2603532T3/es not_active Expired - Lifetime
- 2002-10-11 EP EP10182590.9A patent/EP2348036B1/fr not_active Expired - Lifetime
- 2002-10-11 EP EP10182469.6A patent/EP2341062B1/fr not_active Expired - Lifetime
- 2002-10-11 ES ES10182469.6T patent/ES2625876T3/es not_active Expired - Lifetime
- 2002-10-11 ES ES10182399.5T patent/ES2603531T3/es not_active Expired - Lifetime
- 2002-10-11 KR KR1020047005313A patent/KR101068318B1/ko not_active Expired - Lifetime
- 2002-10-11 ES ES10182298.9T patent/ES2593360T3/es not_active Expired - Lifetime
- 2002-10-11 PT PT101823243T patent/PT2351767E/pt unknown
- 2002-10-11 EP EP10182364.9A patent/EP2348034B1/fr not_active Expired - Lifetime
2004
- 2004-03-24 IL IL161052A patent/IL161052A/en active Protection Beyond IP Right Term
2009
- 2009-03-20 US US12/408,286 patent/US9107873B2/en not_active Expired - Lifetime
- 2009-03-20 US US12/408,076 patent/US20120034261A1/en not_active Abandoned
- 2009-09-10 AU AU2009213040A patent/AU2009213040C1/en active Active
2010
- 2010-01-18 JP JP2010007996A patent/JP5404441B2/ja not_active Expired - Lifetime
2011
- 2011-12-21 US US13/333,123 patent/US8563006B2/en not_active Expired - Fee Related
2012
- 2012-04-25 US US13/455,518 patent/US20120308595A1/en not_active Abandoned
- 2012-04-25 US US13/455,326 patent/US9623101B2/en not_active Expired - Fee Related
- 2012-04-25 US US13/455,268 patent/US9132182B2/en not_active Expired - Lifetime
- 2012-05-18 AU AU2012202916A patent/AU2012202916C1/en active Active
- 2012-10-11 MX MX2015018022A patent/MX349481B/es unknown
2013
- 2013-06-05 US US13/910,187 patent/US8563007B1/en not_active Expired - Fee Related
- 2013-07-31 JP JP2013158937A patent/JP5923070B2/ja not_active Expired - Lifetime
2014
- 2014-07-08 IL IL233545A patent/IL233545A/en active IP Right Grant
2015
- 2015-03-05 US US14/639,543 patent/US9168293B2/en not_active Expired - Lifetime
- 2015-05-18 JP JP2015100931A patent/JP5976880B2/ja not_active Expired - Lifetime
- 2015-07-28 NL NL300755C patent/NL300755I2/nl unknown
- 2015-07-29 LU LU92786C patent/LU92786I2/fr unknown
- 2015-08-06 US US14/820,452 patent/US9757444B2/en not_active Expired - Fee Related
- 2015-08-10 FR FR15C0056C patent/FR15C0056I2/fr active Active
2016
- 2016-03-02 JP JP2016040311A patent/JP5997400B2/ja not_active Expired - Lifetime
- 2016-05-31 IL IL245955A patent/IL245955B/en active IP Right Grant
- 2016-05-31 IL IL245956A patent/IL245956B/en active IP Right Grant
- 2016-07-21 JP JP2016143674A patent/JP2017025061A/ja not_active Withdrawn
2017
- 2017-02-27 US US15/443,618 patent/US10300122B2/en not_active Expired - Lifetime
- 2017-10-11 NL NL300899C patent/NL300899I2/nl unknown
- 2017-10-11 LU LU00040C patent/LUC00040I2/en unknown
- 2017-10-11 LU LU00041C patent/LUC00041I2/en unknown
- 2017-10-11 NL NL300897C patent/NL300897I2/nl unknown
- 2017-10-11 LU LU00042C patent/LUC00042I2/en unknown
- 2017-10-11 NL NL300896C patent/NL300896I2/nl unknown
- 2017-11-10 FR FR17C1042C patent/FR17C1042I2/fr active Active
- 2017-11-10 FR FR17C1043C patent/FR17C1043I2/fr active Active
- 2017-11-10 FR FR17C1044C patent/FR17C1044I2/fr active Active
- 2017-11-23 BE BE2017C055C patent/BE2017C055I2/fr unknown
- 2017-11-23 BE BE2017C057C patent/BE2017C057I2/fr unknown
- 2017-11-23 BE BE2017C056C patent/BE2017C056I2/fr unknown
2018
- 2018-05-22 AU AU2018203627A patent/AU2018203627A1/en not_active Withdrawn
2019
- 2019-02-07 US US16/270,067 patent/US20190151431A1/en not_active Abandoned
2020
- 2020-01-07 US US16/736,619 patent/US11116829B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP3199539A1 (fr)	2017-08-02
CA2463476A1 (fr)	2003-08-07
AU2009213040B2 (en)	2012-03-01
KR20110117726A (ko)	2011-10-27
FR17C1042I1 (fr)	2017-12-22
PT2343308E (pt)	2015-03-25
IL245955A0 (en)	2016-07-31
PT3199539T (pt)	2020-04-01
US8563007B1 (en)	2013-10-22
EP2366707B1 (fr)	2016-09-21
EP2332961B1 (fr)	2016-07-27
US20120301496A1 (en)	2012-11-29
LUC00040I2 (fr)	2017-12-20
EP2348034B1 (fr)	2016-11-02
DK2371838T3 (en)	2016-02-22
ES2625876T3 (es)	2017-07-20
PT2371838E (pt)	2016-03-23
US9132182B2 (en)	2015-09-15
WO2003063766A3 (fr)	2004-01-08
EP2341062A2 (fr)	2011-07-06
EP2371837B1 (fr)	2016-09-21
KR101068318B1 (ko)	2011-09-28
KR101215664B1 (ko)	2012-12-26
US9107873B2 (en)	2015-08-18
US20060257413A1 (en)	2006-11-16
EP2366707A1 (fr)	2011-09-21
US20120034261A1 (en)	2012-02-09
FR17C1043I2 (fr)	2018-12-07
CA2918207A1 (fr)	2003-08-07
ES2561430T3 (es)	2016-02-26
CN1578785A (zh)	2005-02-09
EP2348036A2 (fr)	2011-07-27
FR17C1043I1 (fr)	2017-12-22
LUC00042I1 (fr)	2017-10-16
FR17C1044I1 (fr)	2017-12-22
FR17C1042I2 (fr)	2018-12-07
DK2348036T3 (en)	2016-02-22
BRPI0212999B8 (pt)	2021-07-27
EP2351767B1 (fr)	2015-08-26
DK3199539T3 (da)	2020-04-27
EP2371836B1 (fr)	2016-12-14
FR15C0056I2 (fr)	2016-06-03
NL300896I2 (nl)	2018-04-06
IL233545A (en)	2017-10-31
US20150216960A1 (en)	2015-08-06
US20190151431A1 (en)	2019-05-23
EP1442047A2 (fr)	2004-08-04
EP2351767A2 (fr)	2011-08-03
CN102755631B (zh)	2015-11-25
CN102836426A (zh)	2012-12-26
IL233545A0 (en)	2014-08-31
CA2894296A1 (fr)	2003-08-07
IL161052A0 (en)	2004-08-31
EP2371836A1 (fr)	2011-10-05
LU92786I2 (fr)	2015-11-02
AU2018203627A1 (en)	2018-06-07
EP2343308B1 (fr)	2015-02-18
EP2341062A3 (fr)	2011-09-14
NL300899I1 (nl)	2017-10-20
US8563006B2 (en)	2013-10-22
DK2371836T3 (en)	2017-02-20
EP2351767A3 (fr)	2011-09-14
ES2603532T3 (es)	2017-02-28
NL300899I2 (nl)	2018-04-06
BR0212999A (pt)	2006-05-23
KR20100028657A (ko)	2010-03-12
BE2017C056I2 (fr)	2022-02-01
CA2463476C (fr)	2017-09-12
US9623101B2 (en)	2017-04-18
ES2549765T3 (es)	2015-11-02
US20130259889A1 (en)	2013-10-03
LUC00041I1 (fr)	2017-10-16
PT2348035E (pt)	2015-03-25
BE2017C057I2 (fr)	2022-02-01
EP2371838A1 (fr)	2011-10-05
LUC00042I2 (fr)	2017-12-20
BRPI0212999B1 (pt)	2020-04-28
CN105617372A (zh)	2016-06-01
KR20100121699A (ko)	2010-11-18
MX349481B (es)	2017-07-31
CA2849427C (fr)	2016-10-04
JP2005515771A (ja)	2005-06-02
FR15C0056I1 (fr)	2015-09-11
EP3199539B1 (fr)	2020-03-11
US20120294880A1 (en)	2012-11-22
DK2351767T3 (en)	2015-10-26
CA2894296C (fr)	2018-05-01
NL300896I1 (nl)	2017-10-20
CN102755631A (zh)	2012-10-31
EP2348035A3 (fr)	2011-09-14
JP2015214545A (ja)	2015-12-03
AU2009213040A1 (en)	2009-10-08
EP2371838B1 (fr)	2015-12-16
EP2348035B1 (fr)	2015-02-18
EP2348036A3 (fr)	2011-08-03
JP5997400B2 (ja)	2016-09-28
EP2332961A3 (fr)	2011-07-27
ES2603531T3 (es)	2017-02-28
JP5976880B2 (ja)	2016-08-24
ES2532640T3 (es)	2015-03-30
EP2341063A3 (fr)	2011-09-14
AU2012202916A1 (en)	2012-06-07
EP2348036B1 (fr)	2015-12-16
IL245956A0 (en)	2016-07-31
EP2371837A1 (fr)	2011-10-05
CA2918207C (fr)	2016-10-18
CN102836426B (zh)	2016-09-28
JP2016165275A (ja)	2016-09-15
DK2348035T3 (en)	2015-04-20
DK2341062T3 (en)	2017-05-08
US20150335724A1 (en)	2015-11-26
US20200138933A1 (en)	2020-05-07
EP1442047B1 (fr)	2016-03-16
US20170173140A1 (en)	2017-06-22
AU2009213040C1 (en)	2012-10-11
PT2371836T (pt)	2017-02-17
PT2341062T (pt)	2017-06-02
US20110076299A1 (en)	2011-03-31
LUC00040I1 (fr)	2017-10-16
US10300122B2 (en)	2019-05-28
HK1178429A1 (zh)	2013-09-13
NL300897I2 (nl)	2018-04-06
EP2341063A2 (fr)	2011-07-06
EP2343308A2 (fr)	2011-07-13
CA2939781A1 (fr)	2003-08-07
MX339524B (es)	2016-05-30
EP2343308A3 (fr)	2011-07-27
PT2351767E (pt)	2015-10-30
EP2348034A3 (fr)	2011-09-21
EP2348035A2 (fr)	2011-07-27
FR17C1044I2 (fr)	2018-12-07
IL161052A (en)	2015-04-30
HK1178800A1 (zh)	2013-09-19
CA2849427A1 (fr)	2003-08-07
US9168293B2 (en)	2015-10-27
DK2341063T3 (en)	2015-10-26
JP2014012002A (ja)	2014-01-23
ES2562811T3 (es)	2016-03-08
JP5923070B2 (ja)	2016-05-24
JP2017025061A (ja)	2017-02-02
NL300755I2 (nl)	2025-11-25
LUC00041I2 (fr)	2017-12-20
AU2012202916B2 (en)	2013-08-01
US20120308595A1 (en)	2012-12-06
MXPA04003356A (es)	2004-11-29
DK2332961T3 (en)	2016-10-03
NL300897I1 (nl)	2017-10-20
US11116829B2 (en)	2021-09-14
EP2332961A2 (fr)	2011-06-15
PT2348036E (pt)	2016-03-09
IL245955B (en)	2018-01-31
EP1442047A4 (fr)	2005-06-01
JP5404441B2 (ja)	2014-01-29
EP2341062B1 (fr)	2017-03-29
DK2343308T3 (en)	2015-03-30
KR101099916B1 (ko)	2011-12-28
AU2012202916C1 (en)	2017-06-08
JP2010162023A (ja)	2010-07-29
CA2939781C (fr)	2022-09-13
US20120201844A1 (en)	2012-08-09
US9757444B2 (en)	2017-09-12
WO2003063766A2 (fr)	2003-08-07
CN1578785B (zh)	2013-03-13
EP2348034A2 (fr)	2011-07-27
US8101194B2 (en)	2012-01-24
PT2341063E (pt)	2015-10-29
ES2593360T3 (es)	2016-12-07
ES2549764T3 (es)	2015-11-02
ES2568895T3 (es)	2016-05-05
ES2532639T3 (es)	2015-03-30
ES2609039T3 (es)	2017-04-18
EP2341063B1 (fr)	2015-08-26
ES2781213T3 (es)	2020-08-31
KR20040066793A (ko)	2004-07-27
PT2332961T (pt)	2016-09-28
IL245956B (en)	2019-02-28
ES2615206T3 (es)	2017-06-05

Publication	Publication Date	Title
BE2022C531I2 (fr)	2022-08-09
BE2022C547I2 (fr)	2022-10-19
BE2022C502I2 (fr)	2023-04-12
BE2017C059I2 (fr)	2021-11-22
BE2017C055I2 (fr)	2022-02-01
BE2017C051I2 (fr)	2021-11-22
BE2017C032I2 (fr)	2021-07-19
BE2016C051I2 (fr)	2021-07-19
BE2015C046I2 (fr)	2021-07-19
BE2014C052I2 (fr)	2022-02-01
BE2014C036I2 (fr)	2021-11-22
BE2014C026I2 (fr)	2021-11-22
BE2007C047I2 (fr)	2021-06-04
AU2002307149A8 (fr)	2002-10-21
BE2011C034I2 (fr)	2021-11-22
BE2014C006I2 (fr)	2021-02-04
BRPI0209186B1 (fr)	2012-11-13
BE2017C050I2 (fr)	2021-11-22
BRPI0204884B1 (fr)	2011-05-17
BE2014C008I2 (fr)	2021-02-04
BE2016C021I2 (fr)	2021-03-23
JP2001242811A5 (fr)	2005-10-13
BRPI0101486B8 (fr)	2021-05-25
BE2012C051I2 (fr)	2022-02-02
BRPI0210463A2 (fr)	2017-07-11